Cargando…
Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
Autores principales: | Wang, Jia-Yang, Song, Ya-Qi, Peng, Jing, Luo, Hong-Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320148/ https://www.ncbi.nlm.nih.gov/pubmed/34337271 http://dx.doi.org/10.1021/acsomega.1c02888 |
Ejemplares similares
-
Nanostructured Lipid Carriers Delivering Sorafenib
to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus
Cancer Therapy
por: Wang, Jia-Yang, et al.
Publicado: (2020) -
Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
por: Li, Xin, et al.
Publicado: (2018) -
Nanostructured lipid carrier delivering chlorins e6 as in situ dendritic cell vaccine for immunotherapy of gastric cancer
por: Mao, Mao, et al.
Publicado: (2020) -
Lymph cancer chemotherapy: delivery of doxorubicin–gemcitabine prodrug and vincristine by nanostructured lipid carriers
por: Ni, Shuqin, et al.
Publicado: (2017) -
Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin
por: Han, Yiqun, et al.
Publicado: (2014)